Skip to main content
Biocorp logo

Biocorp — Investor Relations & Filings

Ticker · ALCOR ISIN · FR0012788065 LEI · 969500TKUAME6031UQ32 PA Manufacturing
Open in API
Filings indexed 235 across all filing types
Latest filing 2022-10-10 Regulatory Filings
Country FR France
Listing PA ALCOR

About Biocorp

https://biocorpsys.com

Biocorp designs, develops, and manufactures medical devices and drug delivery systems for the pharmaceutical industry. The company specializes in combining precision engineering with connected technologies to improve patient treatment adherence and outcomes. Its portfolio includes both connected and non-connected devices, such as smart caps for inhalers (Inspair), pen injectors, and systems for drug reconstitution and safety. Biocorp manages the entire value chain, from research and development to manufacturing and final packaging, leveraging its expertise in plastics processing and advanced technological innovation. Since October 2023, Biocorp has been a subsidiary of Novo Nordisk.

Recent filings

Filing Released Lang Actions
Inside Information / Other news releases
Regulatory Filings Classification · 1% confidence The document announces a new partnership and collaboration agreement between BIOCORP and Merck KGaA, Darmstadt, Germany, regarding the development and distribution of a smart drug delivery device (Mallya). It details financial terms (development payments, sales revenues) and strategic implications. This type of announcement, focusing on a significant business development, partnership, or corporate transaction that is not a standard periodic financial report (like 10-K or IR) or a management change, best fits the category for corporate actions or significant business updates. Since it is not a standard regulatory filing like 10-K, nor a specific financing event (CAP), nor a management change (MANG), nor a dividend announcement (DIV), it is most appropriately classified as a general Regulatory Filing (RNS) as it is a material corporate announcement, or potentially a general business update that doesn't fit the highly specific categories. Given the nature of a major partnership announcement, RNS serves as the best fit among the provided options for a material, non-periodic corporate event announcement.
2022-10-10 English
Informations privilégiées / Autres communiqués
Capital/Financing Update Classification · 1% confidence The document announces a new partnership and collaboration agreement between BIOCORP and Merck KGaA regarding the development and distribution of a smart drug delivery device (Mallya). It details financial terms, development milestones, and strategic implications. This type of announcement, focusing on a significant business development, partnership, or strategic agreement that involves future financing/revenue streams but is not a formal regulatory filing like a 10-K or an earnings release, best fits the 'Capital/Financing Update' (CAP) if the focus is heavily on the deal structure and payments, or 'Regulatory Filings' (RNS) as a general business update. Given the explicit mention of development payments up to 5 million euros and potential revenue up to 8 million euros contingent on milestones, it strongly relates to capital/financing activities stemming from a strategic deal. However, since it is a press release announcing a major business deal rather than a pure capital raise or debt issuance, and it doesn't fit the other specific categories (like M&A, ER, IR), the most appropriate classification among the provided options for a significant business development announcement that includes financial considerations is often 'Capital/Financing Update' (CAP) or the general 'Regulatory Filings' (RNS). Since the core event is a strategic partnership with financial components, CAP is a strong candidate. If the document were purely informational without the financial breakdown, RNS might be better. Given the financial details tied to the partnership, I will classify it as CAP, as it details future capital flows contingent on performance.
2022-10-10 French
Informations privilégiées / Communiqué sur comptes, résultats
Interim / Quarterly Report Classification · 1% confidence The document is a press release from BIOCORP announcing its semi-annual financial results for the period ending June 30, 2022. It contains key financial highlights, a management commentary, and a summary table of the income statement. While it mentions that the full 'rapport financier semestriel' is available on their website, the document itself provides substantive financial data and analysis for the interim period, qualifying it as an Interim/Quarterly Report (IR) rather than just a publication announcement. H1 2022
2022-09-29 French
Inside Information / News release on accounts, results
Earnings Release Classification · 1% confidence The document is an earnings release detailing BIOCORP's half-year financial results as of June 30, 2022. It includes key financial highlights, operating results, a CEO commentary, and a summary table of financial performance. While it mentions that the full half-year financial report is available on the website, the document itself provides substantive financial data and analysis, qualifying it as an Earnings Release (ER) rather than a mere Report Publication Announcement (RPA). H2 2022
2022-09-29 English
Inside Information / Other news releases
Regulatory Filings Classification · 1% confidence The document is a press release from BIOCORP announcing the CE marking (regulatory approval) of their SoloSmart device and its compatibility with Sanofi's pens, coinciding with the EASD meeting. It details a product development milestone and mentions future plans, including a reference to 'half year results' on September 29th. This is not a formal regulatory filing (like 10-K or AR), nor is it a transcript, management discussion, or a formal dividend/share change notice. It is a specific announcement regarding a business/product development milestone, which often falls under general regulatory announcements or investor relations communications. Since it is a specific announcement about a regulatory achievement and partnership, and does not fit the definitions for ER, IR, or CAP precisely, it is best classified as a general Regulatory Filing (RNS) as it is a public announcement of a significant event, or potentially LTR if the CE marking is viewed as a regulatory clearance event, but RNS is the broader fit for non-standard press releases.
2022-09-19 English
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 1% confidence The document is a press release announcing a significant business development: BIOCORP obtaining CE marking for its SoloSmart® device and its partnership with SANOFI. It details a product achievement, regulatory milestone (CE marking), and commercial launch plans. This type of announcement, focusing on strategic business updates, product news, and regulatory achievements, is best classified as a general Regulatory Filing (RNS) or potentially a Capital/Financing Update (CAP) if it involved fundraising, but here it is purely operational/product news. Since it is a formal announcement of a business event that doesn't fit neatly into ER, CT, or a specific financial report type, and it is short (3540 chars), it functions as a general regulatory/corporate announcement. Given the options, RNS (Regulatory Filings - general regulatory announcements and fallback) is the most appropriate category for a press release detailing a product milestone and regulatory approval that isn't a standard financial report or management change.
2022-09-19 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.